Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Alan Lau"'
Autor:
Alan Lau, Susan Galbraith, Sonja J. Gill, Mark J. O'Connor, Joshua Armenia, Jacqueline H. L. Fok, Conchita Vens, Rebecca L. Lloyd, Jonathan Cairns, Jenni Nikkilä, Christopher J. Bakkenist, Paul W. G. Wijnhoven
Publikováno v:
Mol Cancer Ther
Radiotherapy is an effective anticancer treatment, but combinations with targeted agents that maximize efficacy while sparing normal tissue are needed. Here, we assess the radiopotentiation profiles of DNA damage response inhibitors (DDRi) olaparib (
Autor:
Sandra Bernaldo de Quirós Fernández, Elaine Cadogan, Charles R. Dunlop, Alan Lau, Frances M. Richards, Timothy Isaac Johnson, Stephen T. Durant, Duncan I. Jodrell, Yann Wallez
Publikováno v:
British Journal of Cancer
BackgroundPersonalised medicine strategies may improve outcomes in pancreatic ductal adenocarcinoma (PDAC), but validation of predictive biomarkers is required. Having developed a clinical trial to assess the ATR inhibitor, AZD6738, in combination wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::183fe9697c845cda96628feea6a69fca
Autor:
James W.T. Yates, Yann Wallez, Charles R. Dunlop, Frances M. Richards, Chiara Fornari, Siang-Boon Koh, Timothy Isaac Johnson, Duncan I. Jodrell, Alan Lau, Sandra Bernaldo de Quirós Fernández
Publikováno v:
Molecular Cancer Therapeutics. 17:1670-1682
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers, and overall survival rates have barely improved over the past five decades. The antimetabolite gemcitabine remains part of the standard of care but shows very limited antitumor e
Autor:
Sébastien L. Degorce, Steven C. Glossop, Alan Lau, Elaine Cadogan, Barlaam Bernard Christophe, Richard Ducray, Kurt Gordon Pike, Andrew G. Thomason, Gilles Ouvry, Allan Dishington, Franck Lach, Lorraine A. Hassall, Thomas M. McGuire, Thorsten Nowak
Publikováno v:
Journal of Medicinal Chemistry. 59:6281-6292
A novel series of 3-quinoline carboxamides has been discovered and optimized as selective inhibitors of the ataxia telangiectasia mutated (ATM) kinase. From a modestly potent HTS hit (4), we identified molecules such as 6-[6-(methoxymethyl)-3-pyridin
Autor:
Zena Wilson, James W.T. Yates, Matthew G Krebs, Kevin J. Harrington, Andrew J. Pierce, Alan Lau, Emma Dean, Magnus T. Dillon, Gemma N Jones
Publikováno v:
Cancer Research. 80:LB-104
Ceralasertib is a potent and selective ATP competitive inhibitor of ataxia telangiectasia and Rad3 related (ATR) in clinical development as monotherapy and in combination with olaparib (Lynparza) and durvalumab (Imfinzi) in patients with advanced sol
Autor:
Ian P. Barrett, Li Zheng, Jason M. Beckta, Jasmine Allen, Antonio Garcia-Trinidad, Aaron Smith, Yingchun Wang, Amrita Sule, Joanne Wilson, Paul Farrington, Andrew G. Thomason, Stephen T. Durant, Victoria Sheridan, Jeremy Karlin, Jenna M. Kahn, Nitai D. Mukhopadhyay, Tianwei Zhang, Jason Grant Kettle, Syed Farhan Ahmad, Nicholas C.K. Valerie, Kan Chen, Barlaam Bernard Christophe, Kurt Gordon Pike, Lucy Riches, Rajesh Odedra, Gareth Hughes, Laura Biddlestone-Thorpe, Kristoffer Valerie, Elaine Cadogan, Martin Pass, Sébastien L. Degorce, Alan Lau, Jennifer L. Vincent, Nicola Colclough, Thomas Anthony Hunt, Bhavika Patel
Publikováno v:
Molecular cancer therapeutics. 17(8)
Inhibition of ataxia-telangiectasia mutated (ATM) during radiotherapy of glioblastoma multiforme (GBM) may improve tumor control by short-circuiting the response to radiation-induced DNA damage. A major impediment for clinical implementation is that
Autor:
Elizabeth Rosenberg, Luis F. Parada, Sumitra Deb, Alan Lau, Mary E. Tokarz, David G. Temesi, Sang Kyun Lim, Muhammad Sajjad, Laura Biddlestone-Thorpe, Kristoffer Valerie, Nicholas C.K. Valerie, Donna Gilfor, Sarah E. Golding, Jason M. Beckta, Nitai D. Mukhopadhyay, Alison F. Wagner, Kevin S. Choe, Bret R. Adams, Mark J. O'Connor, Ashraf Khalil
Publikováno v:
Clinical Cancer Research. 19:3189-3200
Purpose: Glioblastoma multiforme (GBM) is the most lethal form of brain cancer with a median survival of only 12 to 15 months. Current standard treatment consists of surgery followed by chemoradiation. The poor survival of patients with GBM is due to
Autor:
Yan Zhao, Nicola J. Curtin, Suzanne Kyle, Alan Lau, Niall M. B. Martin, Andrew Slade, Michael A. Batey, Caroline Richardson, David R. Newell
Publikováno v:
Molecular Cancer Therapeutics. 12:959-967
Ataxia telangiectasia mutated (ATM) kinase signals DNA double-strand breaks (DSB) to cell-cycle arrest via p53 and DNA repair. ATM-defective cells are sensitive to DSB-inducing agents, making ATM an attractive target for anticancer chemo- and radiose
Publikováno v:
Future medicinal chemistry. 7(7)
In this article, we review the ATR inhibitor field from initial pharmacological tools to first-generation clinical candidates with the potential to bring benefit to cancer patients. ATR is a critical part of the cell DNA-damage response. Over the pas
Autor:
Frances M. Richards, Duncan I. Jodrell, Yann Wallez, Venkata Sai Vivek Bhogadi, Siang-Boon Koh, Alan Lau
Publikováno v:
Molecular Cancer Research. 15:B19-B19
Mutations in oncogenes, tumor suppressor and DNA damage response (DDR) mediator genes drive or permit malignant transformation but also increase endogenous replication stress. The serine/threonine kinase ATR plays a critical role in safeguarding geno